Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: Zactima
Procedure: neoadjuvant therapy

First Posted Date: 2007-04-11

Last Posted Date: 2019-03-26

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00459121

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Gemcitabine
Drug: Bevacizumab
Drug: Carboplatin

First Posted Date: 2007-04-04

Last Posted Date: 2022-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 110

Registration Number: NCT00456261

Locations: 🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States

and more 15 locations

Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Abraxane

First Posted Date: 2007-03-30

Last Posted Date: 2017-07-11

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00454324

Locations: 🇺🇸
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Vinorelbine
Drug: Carboplatin
Drug: Herceptin

First Posted Date: 2007-03-29

Last Posted Date: 2012-03-13

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 88

Registration Number: NCT00453635

Locations: 🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷
Air Forces Military Hospital of Athens, Athens, Greece
🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

and more 7 locations

Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer

Completed

Conditions: Ovarian Neoplasms

Interventions: Drug: Docetaxel
Drug: Carboplatin

First Posted Date: 2007-03-28

Last Posted Date: 2012-08-14

Lead Sponsor: Sanofi

Target Recruit Count: 30

Registration Number: NCT00452985

Locations: 🇧🇩
Sanofi-Aventis, Dhaka, Bangladesh

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Extensive Stage Lung Small Cell Carcinoma
Recurrent Lung Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Drug: Sunitinib Malate

First Posted Date: 2007-03-28

Last Posted Date: 2023-04-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 156

Registration Number: NCT00453154

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Heartland Cancer Research NCORP, Decatur, Illinois, United States
🇺🇸
Illinois CancerCare-Princeton, Princeton, Illinois, United States

and more 122 locations